ChemPlus
Desktop Solid Dispenser for precise powder dispensing
Device · On PremiseCompany source
Company profile
About XtalPi
XtalPi leverages AI, quantum physics, and automation to speed up drug discovery and materials research.
Company description XtalPi official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at XtalPi?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- GPX4-related conditions
- SARM1-related conditions
- various pharmaceutical targets
Who it serves
- Biotech
- Drug Discovery Organizations
- Pharma
Deployment & integration
Cloud Saas · On Premise deployment with recorded integration context.
Geographic context
MarketsChina · Global
Company sourceOfficial website
Company milestones
Platform expansion
First-ever demonstration of SARM1's mechanism using Cryo-EM (2024), Novel GPX4 hits discovery (2024), Nirmatrelvir polymorph research (2024)
Partnerships
Recorded partners
- top pharmaceutical companies worldwide
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
NeoDispenser
Micro-Powder Dispensing System for high-precision material handling
Device · On PremiseCompany source
PatSight
Patent Extraction tool for drug discovery intelligence
Software · Cloud SaaSCompany source
PepiX
Peptide Platform for peptide drug discovery and optimization
Platform · Cloud SaaSCompany source
XFEP
High Accuracy Free Energy Calculation Tool for binding affinity predictions
Software · Cloud SaaSCompany source
XmartChem
Intelligent Synthesis Workstation for automated chemical synthesis
Device · On PremiseCompany source
XMolGen
Generative Chemistry Tool for AI-driven molecular design
Software · Cloud SaaSCompany source
XtalComplete
Intelligent crystallization workstation for automated solid-state research
Device · On PremiseCompany source
XtalCSP
Crystal Structure Prediction software for polymorphic risk assessment
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Toxicological evaluation of peptide compound TSC6: A 13-week subchronic toxicity and genotoxicity study.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · Sep 1, 2026
A Unified Radical C-SuFEx Platform via Catalytic EDA Complex-Mediated S(VI)─F Bond Activation.Angewandte Chemie (International ed. in English) · Jul 1, 2026
Integrating Conformational Sampling and Siamese Learning to Predict Mutation-Induced Binding Affinity Changes in Abelson Tyrosine Kinase and Its Ligands.Journal of chemical theory and computation · Jun 1, 2026
TripKa: Accurate and Scalable Acid-Base Dissociation Property Prediction via Triplet Interaction Networks and Physical Knowledge.Journal of chemical information and modeling · Apr 27, 2026
Discovery of HDM2004, a potent, selective and orally bioavailable HPK1 inhibitor for tumor immunotherapy.European journal of medicinal chemistry · Apr 15, 2026
Committor-regularized learning of differentiable collective variables from non-differentiable structural descriptors.The Journal of chemical physics · Mar 14, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Novel GPX4 hits discovered
28 days discovery timeline
300+ systems derisked
CSP studies since 2017
2-3 weeks CSP completion
regular systems
6-8 weeks CSP completion
complex systems
Undisclosed pharmaceutical partner
Novel hit discovery against GPX4 target
Discovered novel, non-covalent, potent hits against GPX4 in 28 days
Undisclosed research partner
SARM1 mechanism of action demonstration
First-ever demonstration of SARM1's mechanism of action using Cryo-EM
Multiple pharmaceutical partners
Polymorphic risk assessment using crystal structure prediction
Derisked more than 300 systems since 2017 with 100% coverage of experimentally obtained crystalline forms
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from XtalPi
Recent articles published on XtalPi's official website.
XtalPi and VISEN Pharmaceuticals Enter Strategic Partnership to Co-Develop Innovative Endocrine Therapies for a Multi-Billion Dollar Market
Read on XtalPiXtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
Read on XtalPiXtalPi-Powered ReviR Therapeutics Secures Additional NMPA Clinical Approval for “AI+RNA” Rare Disease Pipeline RTX-117
Read on XtalPiXtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
Read on XtalPiLeading Automation Capabilities of XtalPi Recognized by Global Chemical Giant – Successful Launch of Advanced Automated Workstation at BASF
Read on XtalPi07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.